Filing Flows › Humacyte (HUMA) › R&D spending
Humacyte (HUMA) R&D spending by quarter
Humacyte's R&D spending was $18.1M in Q2 2026 (second quarter 2026), -7% from Q1 2026. Over the last 6 quarters it ranged from $14.6M (Q4 2025) to $22.0M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $18.1M | -7% | -18% |
| Q1 2026 | $19.5M | +33% | +26% |
| Q4 2025 | $14.6M | -15% | — |
| Q3 2025 | $17.3M | -22% | — |
| Q2 2025 | $22.0M | +43% | — |
| Q1 2025 | $15.4M | — | — |
Q2 2026 at a glance
Humacyte, Q2 2026: revenue $406K (+35% year over year), net loss $36.8M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Humacyte's R&D spending?
Humacyte's R&D spending was $18.1M in Q2 2026 (second quarter 2026), -7% from Q1 2026.
How has Humacyte's R&D spending changed?
Over the last 6 quarters it ranged from $14.6M (Q4 2025) to $22.0M (Q2 2025).